At a glance
- Originator Roche
- Class Anti-inflammatories; Antihyperglycaemics; Antihyperlipidaemics; Cytoprotectives
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Diabetic neuropathies
Most Recent Events
- 10 Aug 1998 Preclinical development for Atherosclerosis in USA (Unknown route)
- 03 Aug 1998 No-Development-Reported for Diabetic neuropathies (Unknown route)
- 15 Feb 1996 Preclinical development for Diabetic neuropathies (Unknown route)